Cargando…
Beyond cardiovascular medicine: potential future uses of icosapent ethyl
The REDUCE-IT trial demonstrated that icosapent ethyl, an ethyl ester of eicosapentaenoic acid (EPA), reduced cardiovascular events in an at-risk population by a substantial degree. While the cardiovascular protective properties of this compound are now proven, several other potential uses are being...
Autores principales: | Bhatt, Deepak L, Hull, Mark A, Song, Mingyang, Van Hulle, Carol, Carlsson, Cindy, Chapman, M John, Toth, Peter P |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7537800/ https://www.ncbi.nlm.nih.gov/pubmed/33061868 http://dx.doi.org/10.1093/eurheartj/suaa119 |
Ejemplares similares
-
The reduction in cardiovascular risk in REDUCE-IT is due to eicosapentaenoic acid in icosapent ethyl
por: Steg, Ph Gabriel, et al.
Publicado: (2021) -
The Road to Approval: a Perspective on the Role of Icosapent Ethyl in Cardiovascular Risk Reduction
por: Wang, Xiaowen, et al.
Publicado: (2020) -
Potential effects of icosapent ethyl on cardiovascular outcomes in cigarette smokers: REDUCE-IT smoking
por: Miller, Michael, et al.
Publicado: (2022) -
Mechanisms of action, efficacy, and safety of icosapent ethyl: from bench to bedside
por: Bhatt, Deepak L
Publicado: (2020) -
Cardiovascular Benefits of Icosapent Ethyl in Patients With and Without Atrial Fibrillation in REDUCE‐IT
por: Olshansky, Brian, et al.
Publicado: (2023)